U.S. FDA issues four observations to Gland Pharma formulation facility near Hyderabad
The four Form 483 observations followed an unannounced inspection on current good manufacturing practice at the facility in Dundigal between October 12 and 23
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more.
Unlock these with Subscription
The View From India Looking at World Affairs from the Indian perspective.
First Day First Show News and reviews from the world of cinema and streaming.
Today's Cache Your download of the top 5 technology stories of the day.
Science For All The weekly newsletter from science writers takes the jargon out of science and puts the fun in!
Data Point Decoding the headlines with facts, figures, and numbers
THEdge At the cutting edge of education and careers
Health Matters Ramya Kannan writes to you on getting to good health, and staying there
Gender Agenda Stories from beyond the binary.
The Hindu On Books Books of the week, reviews, excerpts, new titles and features.
Updated - October 24, 2026 11:08 am IST - HYDERABAD
The U.S.
Food and Drug Administration (U.S.
FDA) has issued four observations to Gland Pharma’s formulation facility near Hyderabad.
The four Form 483 observations followed an unannounced inspection on current good manufacturing practice (cGMP) at the facility in Dundigal between October 12 and 23.
The observations are procedural in nature and the corrective and preventive actions will be submitted to the U.S.
FDA within the stipulated period.
The observations issued are neither repeat observations nor related to data integrity, the company said in a filing on Friday (October 24, 2026).
Gland Pharma shares closed 1.17% lower at ₹2,825.35 apiece on the BSE.
Terms & conditions | Institutional Subscriber
Comments have to be in English, and in full sentences.
They cannot be abusive or personal.
Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform.
If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles.
If you do not have an account please register and login to post comments.
Users can access their older comments by logging into their accounts on Vuukle.
Full detailed coverage is shown on the council website above. Source attribution: The Hindu – Business.
Back to all council news
